Mel Mann shares his inspiring 30-year journey with chronic myeloid leukemia, from a terminal diagnosis to long-term survival.

Kolibaba, KS, Druker BJ. Current Status of Treatment for Chronic Myelogenous Leukemia. MedGenMed 2(2), 2000 [formerly published in Medscape Hematology-Oncology eJournal 3(2), 2000]. Available at ...

Opens in a new tab or window The rare hematologic malignancy known as chronic myelomonocytic leukemia ... in CML are unclear. A new study found that mutations in activated signaling and myeloid ...

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...

Medically reviewed by Doru Paul, MD Leukemia is a cancer that changes blood cells. It usually develops in the bone marrow, ...

Updated 96-week data from the ASC4FIRST trial show asciminib significantly outperforms standard TKIs in major molecular ...

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel ...

The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill.

Open a VIP account (an enterprise account with priority handling, 24/7 dedicated customer care, unlimited usage/users, help on formatting, standards, rules, regulations, policy compliance, etc., and ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia ...